These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 29950538

  • 1. Comparison of Deferiprone to Deferasirox and Deferoxamine to Cardiac and Hepatic T2* MRI in Thalassemia Patients: Evidence-based Case Report.
    Wahidiyat PA, Yosia M, Sari TT.
    Acta Med Indones; 2018 Apr; 50(2):168-176. PubMed ID: 29950538
    [Abstract] [Full Text] [Related]

  • 2. Longitudinal prospective comparison of pancreatic iron by magnetic resonance in thalassemia patients transfusion-dependent since early childhood treated with combination deferiprone-desferrioxamine vs deferiprone or deferasirox monotherapy.
    Ricchi P, Meloni A, Pistoia L, Gamberini MR, Cuccia L, Allò M, Putti MC, Spasiano A, Rosso R, Cecinati V, Righi R, Renne S, Peritore G, Vallone A, Positano V, Quaia E, Cademartiri F, Pepe A.
    Blood Transfus; 2024 Jan; 22(1):75-85. PubMed ID: 37146300
    [Abstract] [Full Text] [Related]

  • 3. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients.
    Cassinerio E, Orofino N, Roghi A, Duca L, Poggiali E, Fraquelli M, Zanaboni L, Cappellini MD.
    Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580
    [Abstract] [Full Text] [Related]

  • 4. Comparative efficacy and safety of deferoxamine, deferiprone and deferasirox on severe thalassemia: a meta-analysis of 16 randomized controlled trials.
    Xia S, Zhang W, Huang L, Jiang H.
    PLoS One; 2013 Sep; 8(12):e82662. PubMed ID: 24376563
    [Abstract] [Full Text] [Related]

  • 5. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
    Fischer R, Piga A, Harmatz P, Nielsen P.
    Ann N Y Acad Sci; 2005 Sep; 1054():350-7. PubMed ID: 16339683
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E, Komninaka V, Karavas A, Terpos E, Akianidis V, Christoulas D.
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [Abstract] [Full Text] [Related]

  • 7. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging.
    Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A.
    Haematologica; 2011 Jan; 96(1):41-7. PubMed ID: 20884710
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI.
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN, Kontoghiorghes GJ.
    Drug Des Devel Ther; 2016 Nov; 10():465-81. PubMed ID: 26893541
    [Abstract] [Full Text] [Related]

  • 10. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience.
    Karakas Z, Yilmaz Y, Bayramoglu Z, Karaman S, Aydogdu S, Karagenc AO, Tugcu D, Dursun M.
    Radiol Med; 2018 Aug; 123(8):572-576. PubMed ID: 29663188
    [Abstract] [Full Text] [Related]

  • 11. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
    Totadri S, Bansal D, Bhatia P, Attri SV, Trehan A, Marwaha RK.
    Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
    [Abstract] [Full Text] [Related]

  • 12. Cardiac events and cardiac T2* in Egyptian children and young adults with beta-thalassemia major taking deferoxamine.
    Elalfy MS, Abdin IA, El Safy UR, Ibrahim AS, Ebeid FS, Salem DS.
    Hematol Oncol Stem Cell Ther; 2010 Sep; 3(4):174-8. PubMed ID: 21150236
    [Abstract] [Full Text] [Related]

  • 13. Cardiac and hepatic iron and ejection fraction in thalassemia major: multicentre prospective comparison of combined deferiprone and deferoxamine therapy against deferiprone or deferoxamine monotherapy.
    Pepe A, Meloni A, Rossi G, Cuccia L, D'Ascola GD, Santodirocco M, Cianciulli P, Caruso V, Romeo MA, Filosa A, Pitrolo L, Putti MC, Peluso A, Campisi S, Missere M, Midiri M, Gulino L, Positano V, Lombardi M, Ricchi P.
    J Cardiovasc Magn Reson; 2013 Jan 16; 15(1):1. PubMed ID: 23324167
    [Abstract] [Full Text] [Related]

  • 14. Recent developments in iron chelation therapy.
    Cario H, Janka-Schaub G, Janssen G, Jarisch A, Strauss G, Kohne E.
    Klin Padiatr; 2007 Jan 16; 219(3):158-65. PubMed ID: 17525910
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of iron chelators in thalassemia and sickle cell disease: a multiple treatment comparison network meta-analysis and trial sequential analysis.
    Sridharan K, Sivaramakrishnan G.
    Expert Rev Clin Pharmacol; 2018 Jun 16; 11(6):641-650. PubMed ID: 29727586
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of deferasirox for reducing total body and cardiac iron in thalassemia.
    Merchant R, Ahmed J, Krishnan P, Jankharia B.
    Indian Pediatr; 2012 Apr 16; 49(4):281-5. PubMed ID: 21992861
    [Abstract] [Full Text] [Related]

  • 17. Uses and limitations of serum ferritin, magnetic resonance imaging T2 and T2* in the diagnosis of iron overload and in the ferrikinetics of normalization of the iron stores in thalassemia using the International Committee on Chelation deferiprone/deferoxamine combination protocol.
    Kolnagou A, Yazman D, Economides C, Eracleous E, Kontoghiorghes GJ.
    Hemoglobin; 2009 Apr 16; 33(5):312-22. PubMed ID: 19814677
    [Abstract] [Full Text] [Related]

  • 18. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions.
    Neufeld EJ.
    Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major.
    Perifanis V, Christoforidis A, Vlachaki E, Tsatra I, Spanos G, Athanassiou-Metaxa M.
    Int J Hematol; 2007 Dec 01; 86(5):385-9. PubMed ID: 18192103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.